Skip to main content
SpringerLink
Log in

Relationship Between Metabolic Control and Complications in Diabetes

Therapeutic Implications of the Diabetes Control and Complications Trial

  • Chapter
Type 1 Diabetes

Part of the book series: Contemporary Endocrinology ((COE))

  • 561 Accesses

Abstract

The Diabetes Control and Complications Trial (DCCT) was organized in 1982 in order to address definitively the question of whether the long-term complications of type 1 diabetes were directly related to hyperglycemia and whether the risks of these complications could be significantly reduced by lowering blood glucose levels to near normal. The question was of great scientific and public health importance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. LaPorte RE, Matsushima M, Chang YE Prevalence and incidence of insulin-dependent diabetes. Diabetes in America, 2nd ed. National Institutes of Health, Washington, DC, 1995.

    Google Scholar 

  2. Deckert T, Pulsen JE, Larsen M. Prognosis of diabetics with onset before the age of thirty-one. I. Causes of death and complications. Diabetologia 1978;14:363–370.

    Article  PubMed  CAS  Google Scholar 

  3. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676–1685.

    Article  PubMed  CAS  Google Scholar 

  4. Deckert T, Pulsen JE, Larsen M. Prognosis of diabetics with onset before the age of thirty-one. II. Factors influencing the prognosis. Diabetologia 1978;14:371–377.

    Article  PubMed  CAS  Google Scholar 

  5. Genuth SM. The case for blood glucose control. Adv Int Med. 1995;40:573–623.

    CAS  Google Scholar 

  6. Engerman R, Bloodworth JMB Jr, Nelson S. Relationship of micro-vascular disease in diabetes to metabolic control. Diabetes 1977;26:760–769.

    Article  PubMed  CAS  Google Scholar 

  7. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138–148.

    PubMed  CAS  Google Scholar 

  8. Brownlee M. Negative consequences of glycation. Metabolism 2000;49:9–13.

    Article  PubMed  CAS  Google Scholar 

  9. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1–9.

    Article  PubMed  CAS  Google Scholar 

  10. Carrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic glycation in the pathogenesis of diabetic neuropathy: a critical review for the end of the 20th century. Diabetes Rev 1999;7:275–299.

    Google Scholar 

  11. Ishii H, Daisuke K, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998;76:21–31.

    Article  PubMed  CAS  Google Scholar 

  12. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: A multicenter study. Clin Chem 1987;33:2267–2271.

    Google Scholar 

  13. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT) design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530–545.

    Article  Google Scholar 

  14. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.

    Article  Google Scholar 

  15. The DCCT Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Opthalmol 1995;113:36–51.

    Article  Google Scholar 

  16. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 1995;102:647–661.

    Google Scholar 

  17. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703–1720.

    Article  Google Scholar 

  18. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561–568.

    Article  Google Scholar 

  19. The DCCT Research Group. Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial. Ann Neurol 1995;38:869–880.

    Article  Google Scholar 

  20. The DCCT Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415–1427.

    Article  Google Scholar 

  21. The DCCT Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361–376.

    Article  Google Scholar 

  22. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994;125:177–188.

    Article  Google Scholar 

  23. Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994;43:1378–1389.

    Article  PubMed  CAS  Google Scholar 

  24. Pampanelli S, Fanelli C, Lalli C, et al. Long-term intensive insulin therapy in IDDM: effects on HbA 1 c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia 1996;39:677–686.

    Article  PubMed  CAS  Google Scholar 

  25. Wahren J, Ekberg K, Fernqvist-Forbes E, et al. Brain substrate utilisation during acute hyperglycaemia. Diabetologia 1999;42:812–818.

    Article  PubMed  CAS  Google Scholar 

  26. Gale EAM, Tattersal RB. Unrecognized nocturnal hypoglycemia in insulin-treated diabetes. Lancet 1979;1:1049–1052.

    Article  PubMed  CAS  Google Scholar 

  27. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991;90:450–459.

    Google Scholar 

  28. The DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286.

    Article  Google Scholar 

  29. The DCCT Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996;124:379–388.

    Article  Google Scholar 

  30. Kramer L, Fasching P, Madl C, et al. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 1998;47:1909–1914.

    Article  PubMed  CAS  Google Scholar 

  31. The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care 1988;11:567–573.

    Article  Google Scholar 

  32. Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure. Results from the DCCT. JAMA 1998;280: 140–146.

    Article  PubMed  CAS  Google Scholar 

  33. Sibley SD, Hokanson JE, Steffes MW, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999;22:1165–1170.

    Article  PubMed  CAS  Google Scholar 

  34. The DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894–903.

    Article  Google Scholar 

  35. The DCCT Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the Diabetes Control and Complications Trial. Diabetes Care 1996;19:195–203.

    Article  Google Scholar 

  36. The DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968–983.

    Article  Google Scholar 

  37. Krolewski AS, Laffel LMB, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251–1255.

    Article  PubMed  CAS  Google Scholar 

  38. Warram JH, Manson JE, Krolewski As. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1035–1036.

    Article  Google Scholar 

  39. The DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45: 1289–1298.

    Article  Google Scholar 

  40. The DCCT Research Group. Effect of intensive therapy on residual B-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517–523.

    Article  Google Scholar 

  41. The DCCT Research Group. Effects of age, duration and treatment on insulin-dependent diabetes mellitus on residual B-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30–36.

    Article  Google Scholar 

  42. The DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381–389.

    Article  Google Scholar 

  43. White NH, Cleary PA, Dahms W, et al. Prolonged effects of DCCT intensive therapy (INT) in adolescents on diabetes complications after four years of follow-up in Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes 2000;49(Suppl 1):A47-A48.

    Google Scholar 

  44. The DCCT Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997;46:1829–1839.

    Article  Google Scholar 

  45. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes 1999;48:870–880.

    Article  PubMed  CAS  Google Scholar 

  46. EDIC Study Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99–111.

    Article  Google Scholar 

  47. Kolterman O, Lorenzi G. Self-care practices and outcomes in the DCCT cohort two years post-completion: EDIC follow-up study. Diabetes 1996;45:124A.

    Google Scholar 

  48. The EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM complications study. Diabetologia 1994;37:278–285.

    Article  Google Scholar 

  49. European IDDM Policy Group. Consensus guidelines for the management of insulin-dependent (type 1) diabetes. Diabet Med 1993;10:990.

    Article  Google Scholar 

  50. Davis EA, Keating B, Byrne GC, et al. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997;20:22–25.

    Article  PubMed  CAS  Google Scholar 

  51. Dorchy H, Roggemans M-P, Willems D. Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care 1997;20:2–6.

    Article  PubMed  CAS  Google Scholar 

  52. Bourgnères PF, Landais P, Mairesse AM, et al. Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents. Diabetes Care 1993;16:94–102.

    Article  Google Scholar 

  53. Rosilio M, Cotton J-B, Wieliczko M-C, et al. Factors associated with glycemic control: a cross-sectional nationwide study in 2,579 French children with type 1 diabetes. Diabetes Care 1998;21:1146–1153.

    Article  PubMed  CAS  Google Scholar 

  54. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Diabetes Care 1997;20:714–720.

    Article  PubMed  CAS  Google Scholar 

  55. Mortensen HB, Robertson KJ, Aanstoot H-J, et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Diabet Med 1998;15:752–759.

    Article  PubMed  CAS  Google Scholar 

  56. Rohlfing CL, Little RR, Wiedmeyer H-M, et al. Improved glycemic control in childhood diabetes: a 16-year study. Diabetes 2000;49:A93-A94.

    Google Scholar 

  57. Boland EA, Grey M, Oesterle A, et al. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999;22:1779–1784.

    Article  PubMed  CAS  Google Scholar 

  58. Kostraba JN, Dorman JS, Orchard TJ. Contribution of diabetes-duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 1989;12:686–693.

    Article  PubMed  CAS  Google Scholar 

  59. Donaghue KC, Fung ATW, Hing S, et al. The effect of prepubertal diabetes duration on diabetes: microvascular complications in early and late adolescence. Diabetes Care 1997;20:77–80.

    Article  PubMed  CAS  Google Scholar 

  60. Danne T, Kordonouri O, Hövener G, et al. Diabetic angiopathy in children. Diabet Med 1997;14:1012–1025.

    Article  PubMed  CAS  Google Scholar 

  61. Lobefalo L, Verrotti A, Della Loggia G, et al. Diabetic retinopathy in childhood and adolescence: effect of puberty. Diabet Nutr Metab 1997;10:193–197.

    Google Scholar 

  62. Ryan CM, Atchison J, Puczynski S. Mild hypoglycemia associated with deterioration of mental efficiency in children with insulin dependent diabetes mellitus. J Pediatr 1990;117:32–38.

    Article  PubMed  CAS  Google Scholar 

  63. Ryan C, Vega A, Drash A. Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 1985;75:921–927.

    PubMed  CAS  Google Scholar 

  64. Northam EA, Anderson PJ, Werther GA, et al. Neuropsychological complications of IDDM in children 2 years after disease onset. Diabetes Care 1998;21:379–384.

    Article  PubMed  CAS  Google Scholar 

  65. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999;22:1785–1789.

    Article  PubMed  CAS  Google Scholar 

  66. Lepore M, Pampanelli S, Fanelli CG, et al. Pharmacokinetics and dynamics of s.c. injection of insulin glargine, NPH and ultralente in T 1 DM: comparison with CSII. Diabetes 2000;49(Suppl 1):A9.

    Google Scholar 

  67. Pieber TR, Eugene-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157–162.

    Article  PubMed  CAS  Google Scholar 

  68. Chase HP, Peery BN, Shepherd ME, et al. The impact of the DCCT and of humalog treatment on glycohemoglobin (HbA 1c) and hypoglycemia in type 1 diabetes. Diabetes 1999;48:A 100.

    Google Scholar 

  69. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501–1506.

    Article  PubMed  CAS  Google Scholar 

  70. Shapiro J, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230–238.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Saul Genuth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Mark A. Sperling MD (Professor of Pediatrics and Chair Emeritus) (Professor of Pediatrics and Chair Emeritus)

  2. Division of Endocrinology, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Mark A. Sperling MD (Professor of Pediatrics and Chair Emeritus) (Professor of Pediatrics and Chair Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Genuth, S. (2003). Relationship Between Metabolic Control and Complications in Diabetes. In: Sperling, M.A. (eds) Type 1 Diabetes. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-310-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-310-1_11

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-258-2

  • Online ISBN: 978-1-59259-310-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation